Form 4: Director Christi Shaw Receives Beam Therapeutics Options

Director Christi Shaw was granted 19,676 stock options in Beam Therapeutics Inc. as part of standard equity compensation.

Summary

• Director Christi Shaw acquired 19,676 stock options in Beam Therapeutics Inc. (BEAM).
• The options have an exercise price of $29.55 per share.
• The grant date for these derivative securities is June 3, 2026.
• The options are set to expire on June 3, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of Beam Therapeutics common stock.

Future Outlook

The options vest in full on the earlier of the first anniversary of the grant date or immediately prior to the next annual meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard compensation packages for mid-cap biotechnology firms.
• Vesting schedules tied to annual meetings are common practice among NASDAQ-listed life sciences companies.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of June 3, 2027, or the date of the 2027 annual meeting of stockholders.

Key Dates

Keywords

Beam Therapeutics, BEAM, Form 4, Insider Trading, Stock Options, Director Compensation